Lorat (Lorazepam)

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lorat (Lorazepam)

Property Description
Active ingredient Lorazepam (INN)
Form Tablet (oral/sublingual), Oral Solution, Injectable Solution
Pharmacological class Benzodiazepine, CNS Depressant
General purpose Anxiolytic and Sedative-hypnotic
Origin Synthetic Compound

What Type of Medicine is Lorat (Lorazepam)?

Lorat contains the active ingredient Lorazepam, which is classified as a high-potency benzodiazepine derivative, a widely recognized synthetic compound in pharmaceutical chemistry. This substance belongs to a pharmacological group centrally defined by its actions as an anxiolytic (anti-anxiety agent), a sedative-hypnotic (sleep-inducing agent), an anticonvulsant, and a muscle relaxant. Lorazepam is recognized for its inhibitory effect on the central nervous system (CNS), functioning as an agent for providing acute calming.

A unique differentiating factor for Lorazepam, compared to some older benzodiazepines, is its metabolic pathway: it undergoes direct glucuronidation in the liver. This process is generally less susceptible to being affected by concurrent medications, offering an advantage in complex clinical scenarios. This simplified clearance makes the drug's activity profile more predictable.

Composition, Forms, and General Purpose

The medication is a single-ingredient product, featuring the poorly water-soluble Lorazepam compound. Because of its solubility profile, it is manufactured in several dosage forms to ensure versatility in therapeutic application. These include the standard tablet for oral or sublingual intake, an oral solution concentrate, and a sterile injectable solution for acute, rapid interventions.

The overall goal of administering Lorazepam is to leverage its potent dampening effect on nerve cell firing, which fosters generalized relaxation and aids in easing states of intense tension. The injectable form, for instance, requires specialized vehicles, such as Propylene Glycol and Polyethylene Glycol, to ensure the substance remains dissolved and can be administered effectively.

Regulatory References

  1. Lorazepam: MedlinePlus Drug Information
  2. Lorazepam - StatPearls - NCBI Bookshelf

What side effects are possible with Lorat (Lorazepam)?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential effects of Lorazepam primarily based on the drug's action as a central nervous system (CNS) depressant. The adverse reaction profile is structured by frequency, systemic impact, and severity.

Adverse Reaction Classifications

The most common adverse reactions listed in regulatory data relate to the CNS, including drowsiness, sedation, fatigue, dizziness, and unsteadiness (ataxia). Less common or rare systemic effects have also been documented across several system-organ classes, such as Psychiatric Disorders (e.g., confusion, depression, or paradoxical reactions like agitation), Gastrointestinal Disorders (e.g., nausea, constipation), and Hepatobiliary Disorders (e.g., jaundice or elevated liver enzymes).

Serious Adverse Reactions and Key Constraints

The regulatory safety profile highlights severe risks. These include the potential for profound sedation, respiratory depression, coma, and death when Lorazepam is used concurrently with other CNS depressants, particularly opioids, as detailed in official warnings. Rare, severe immunological reactions, such as anaphylaxis and angioedema, are also noted. Lorazepam is formally contraindicated in specific patient situations, including those with acute narrow-angle glaucoma or Myasthenia Gravis.

Exposure-Related Safety Patterns

Official safety information states that the risk of developing physical and psychological dependence increases in relation to the dose used and the duration of treatment. Tolerance to the initial sedative effects may develop over time. Following discontinuation, potentially severe withdrawal reactions, including seizures, are documented risks, which may occur even after short-term use.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the Lorazepam overdose profile based on the severity of Central Nervous System (CNS) depression and required emergency action. Documented overdose presentations typically progress through a spectrum of symptoms, including drowsiness, confusion, extreme tiredness, slurred speech, and problems with coordination.

Physiological systems affected include the CNS and respiratory system. Severity outcomes can escalate to profound sedation, loss of consciousness, and life-threatening conditions such as respiratory depression, respiratory arrest, and coma. Co-ingestion with other CNS depressants, such as opioids or alcohol, is documented by regulators as significantly increasing the risk of these severe and potentially fatal outcomes.

Emergency-Response Statements mandate that if an overdose is suspected, or if the individual exhibits severe symptoms like trouble breathing, inability to be awakened, or collapse, one must Seek Immediate Medical Attention or Call Emergency Services immediately.

The official approach to management is rooted in supportive care, with necessary steps taken for airway management. A specific competitive antagonist, Flumazenil, is available; however, regulatory documents note its use carries the risk of precipitating acute withdrawal reactions or seizures, especially in individuals with chronic benzodiazepine exposure. Elderly or debilitated patients are specifically noted as being more susceptible to the severe sedative effects of an overdose.

Therapeutic Uses of Lorat (Lorazepam)

What Lorat (Lorazepam) Treats: Main Uses and Benefits

The medication is commonly used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. It is considered relevant in clinical settings marked by heightened patient distress. The primary therapeutic domains include providing symptomatic relief for anxiety disorders, addressing continuous seizure activity (Status Epilepticus), and managing acute agitation, along with providing support before medical procedures.

Lorat is applied when symptoms escalate, addressing symptom clusters that may become intense or disruptive, such as overwhelming worry, excessive restlessness, physical tension, and sleep disruption caused by acute anxiety.

“The medication provides support that helps ease the overall symptom burden.”

In clinical crises, it is applied during phases when symptoms become more noticeable, where short-term symptomatic assistance is needed for conditions like alcohol withdrawal syndrome. This support helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.


Quick Fact: Relief for Acute Tension Lorat is commonly used in settings where short-term symptom stabilization is important, providing support during episodes of heightened psychological and physical tension, which contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. FDA DailyMed Lorazepam Label

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility profiles for Lorazepam based strictly on government regulatory documents (e.g., FDA, EMA). Use is generally intended for short-term periods only.

Populations Who Must NOT Use Lorazepam (Contraindications)

Condition / Population Status Rationale (Official Labeling)
Hypersensitivity Contraindicated Known allergy to lorazepam or other benzodiazepines.
Acute Narrow-Angle Glaucoma Contraindicated Must be avoided.
Myasthenia Gravis Contraindicated Muscle-weakening effects pose risk.
Severe Hepatic Insufficiency Contraindicated Risk of precipitating hepatic encephalopathy.
Severe Respiratory Insufficiency Contraindicated Risk of further respiratory depression.
Sleep Apnea Syndrome Contraindicated Risk of worsened breathing difficulty.

Populations Requiring Restricted or Conditional Use

  • Elderly and Debilitated Patients: Use requires a reduced initial dosage and frequent monitoring due to increased susceptibility to sedation and unsteadiness.
  • Children and Adolescents: Safety and effectiveness for oral use are not established in children under 12 years of age (some labels cite ge 12 or ge 16 for eligibility).
  • Pregnancy: Not generally recommended and should be avoided, especially in the first and late trimesters. The patient should be warned of potential risks to the fetus.
  • Breastfeeding: Not recommended. Lorazepam is excreted into human milk and may cause adverse effects in the infant (e.g., sedation).
  • Liver/Kidney Impairment: Use with caution; careful dosage adjustment and monitoring are required.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lorat (Lorazepam) has officially documented interactions that are classified primarily based on enhanced central nervous system (CNS) depression and alteration of its metabolic clearance.

Pharmacodynamic Interactions

Co-administration with other CNS depressants, including opioids, alcohol (ethanol), barbiturates, antipsychotics, and sedative antihistamines, results in an officially documented additive effect. This pharmacodynamic interaction increases the risk of profound sedation, respiratory depression, coma, and death. Specific agents like Clozapine may additionally produce marked sedation, hypotension, and respiratory arrest, as noted in the regulatory labeling. Due to this risk, concomitant use with opioids must adhere to the lowest effective dosages and minimum necessary duration, while use with alcohol and sodium oxybate should be avoided.

Pharmacokinetic and Clearance Interactions

Lorazepam's metabolic profile is defined by direct glucuronidation, minimizing interaction risk with CYP enzymes. However, substances that inhibit glucuronidation, such as Valproate and Probenecid, are documented to reduce Lorazepam's total clearance and increase its plasma concentration. Regulatory guidelines state that if a UGT inhibitor is initiated, the Lorazepam dose must be reduced. Additionally, the administration of Flumazenil is a formally contraindicated combination in patients physically dependent on benzodiazepines due to the documented risk of precipitating acute withdrawal. The sedative effects of these interactions are noted to be more pronounced in elderly or debilitated patients.

Mechanism of Action

Lorat (Lorazepam) functions as a positive allosteric modulator on the central nervous system’s gamma-aminobutyric acid type A (GABAA) receptor complex. This pentameric ligand-gated chloride channel is the principal inhibitory neurotransmitter receptor in the brain.

Lorazepam binds to a specific allosteric site located in the cleft between the alpha and gamma subunits of the GABAA receptor. This interaction does not directly activate the channel but induces a conformational change in the receptor protein. This structural modification results in an enhanced affinity of the endogenous agonist, GABA, for its own binding sites, thereby potentiating the inhibitory effect of GABA.

Binding of GABA to the potentiated receptor complex increases the frequency of chloride ion (Cl^-) channel opening. This causes an influx of negatively charged chloride ions into the postsynaptic neuron. The intracellular accumulation of Cl^- leads to hyperpolarization of the neuronal plasma membrane, decreasing the neuron’s excitability and making it more resistant to excitatory stimuli. The downstream cascade is a widespread inhibition of neuronal activity throughout the central nervous system, resulting in system-level depression of cortical and limbic function, and modulation of muscle tone via spinal cord pathways.

Dosage and Administration Information

The administration of Lorazepam follows specific protocols, including different routes and dose schedules for various contexts.

Administration Scope

Property Instruction
Route of Administration Oral (tablets, concentrate, extended-release capsule), Intravenous (IV), and Intramuscular (IM).
Standard Dosing Oral doses for ongoing use typically range from 2 mg to 6 mg per day in divided doses, with a maximum daily dose generally not exceeding 10 mg. Single oral doses for bedtime use are typically 2 mg to 4 mg.
Frequency Pattern Oral dosing is most often administered in divided doses two or three times daily, or as a single dose at bedtime. The extended-release capsule is administered once daily in the morning.
Preparation Requirements The injectable solution must be diluted 1:1 with a compatible solution (e.g., Normal Saline) immediately prior to IV use, and the injection rate must not exceed 2 mg per minute.
Population-Specific Rules The initial oral dosage for older or debilitated adults should be reduced by approximately 50%, with the initial dosage generally not exceeding 2 mg per day.

Use Protocol and Duration

Lorazepam is indicated for short-term use only, and continuous treatment beyond approximately four months has not been systematically evaluated in clinical studies. Because of this short-term restriction, discontinuation following extended administration requires a gradual dose reduction (tapering). Oral forms can generally be taken with or without food, but extended-release capsules must be swallowed whole and not crushed.

Recent Clinical Evidence

Research evidence / Overview of studies for Lorat (Lorazepam)


Evidence for Short-Term Relief of Anxiety Symptoms

Research exploring the use of Lorat involves short-term Randomized Controlled Trials (RCTs) that explored how symptoms change over time. These studies were applied in patient populations to examine symptom intensity or variability. Research examined outcomes related to patient-reported discomfort and changes in anxiety severity, using clinical rating scales.

Findings describe patterns observed in these studies, reporting measurements taken during the defined, acute phase. The evidence contributes to the broader characterization of short-term symptom patterns. However, the existing research is primarily relevant in trials assessing short-term or episodic symptom patterns. The follow-up durations were limited, meaning that long-term effects are not fully established.


Evidence for Use in Acute Crisis: Continuous Seizures and Alcohol Withdrawal

Research scenarios focusing on acute or disruptive episodes, such as Status Epilepticus and Alcohol Withdrawal Syndrome (AWS), examined Lorat. Studies monitored responses over defined time intervals, with researchers examining the time elapsed until the cessation of convulsive activity or monitoring withdrawal severity using specialized clinical scales.

In these acute settings, data show patterns related to the monitored time-course of outcomes such as seizure cessation or withdrawal severity. For continuous seizure activity, research describes the percentage of participants where cessation of the episode was observed. It was observed in some studies that findings were mixed when other active treatments were used as a comparator.


Evidence Gaps and Research Uncertainty

Overall, the evidence highlights what is known and what is still uncertain about Lorat. Research provides context for short-term, acute, and episodic use, but the breadth of data for certain groups, such as older adults with impaired kidney function, remains insufficient. Specifically, there is limited information for long-term outcomes, and the certainty remains low regarding the full profile of use beyond the acute phase. Comparative evidence with other treatments is an area where research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Lorat (Lorazepam) (FAQ)


Q: Can Lorat be used by elderly people?

Official labeling notes that older or debilitated adults may be more sensitive to the effects of lorazepam. Because of this potential sensitivity, the initial dosage for this population is generally lower, as indicated in the official labeling.

Q: What is the risk of withdrawal symptoms if Lorat use is stopped?

Regulatory documents state that continued use of lorazepam exposes users to the risk of developing physical dependence. Stopping use abruptly or reducing the dose too quickly may lead to acute withdrawal reactions. These reactions can be serious, and official information notes that discontinuation requires caution.

Q: What are the major contraindications listed for Lorat use?

According to official product information, lorazepam is contraindicated if a person has acute narrow-angle glaucoma. It is also contraindicated for those with a known history of allergic reactions to any benzodiazepine medication.

Q: What is the official purpose of the Boxed Warning (Black Box) for Lorat?

The Boxed Warning is included in the official labeling to alert users to the serious risks associated with the medication. These risks include abuse, misuse, addiction, dependence, and withdrawal reactions. The warning specifically highlights the risk of profound sedation and respiratory depression that can occur when lorazepam is taken with opioid medicines.

Q: Is Lorat used in combination with other mental health medications?

Regulatory labeling notes that lorazepam is a central nervous system (CNS) depressant. Caution is advised when it is co-administered with other CNS depressants, including medications like antipsychotics, which are often used for mental health. This combination can increase the risk of enhanced sedation and respiratory depression.

Q: Can certain medical conditions prevent a person from being eligible for Lorat?

Official documents list medical conditions that serve as reasons for caution or contraindication. These include acute narrow-angle glaucoma, severe respiratory issues (such as sleep apnea), and severe hepatic (liver) insufficiency.

Q: What is meant by the 'sedative' property of Lorat?

Lorazepam is officially described as having a sedative property, which means it causes a calming or tranquilizing effect. This effect results from its action on chemical messengers in the brain, leading to widespread inhibition of nerve activity and depression of cortical function.

Q: What is the main reason Lorat is prescribed?

Official regulatory documents indicate that lorazepam is prescribed for the management of anxiety disorders or for the short-term relief of anxiety symptoms, including anxiety associated with depressive symptoms.

Q: Is Lorat the same kind of medication as Xanax (Alprazolam)?

Regulatory classification indicates that lorazepam (Lorat) and alprazolam (Xanax) are both benzodiazepines. They are both designated as Schedule IV controlled substances in the United States.

Q: What kind of 'schedule' or classification does Lorat have?

Lorazepam is classified as a Schedule IV controlled substance under the Controlled Substances Act in the United States. This classification indicates the medication carries a potential for abuse and dependence.

Q: How quickly does Lorat usually start to work after taking it?

Studies noted in official product information indicate that after a person takes lorazepam by mouth, the medication typically reaches its peak concentration in the blood within a few hours. The onset of effect may vary among individuals.

Q: How long can the effects of Lorat typically be felt?

The effects of a single dose are related to the drug's half-life, which is the time it takes for half of the medication to be eliminated from the body. The serum elimination half-life of lorazepam is generally reported to range between 12 and 15 hours.

Q: Does Lorat cause a feeling of drowsiness or sleepiness?

According to the official adverse reactions section, drowsiness, or sleepiness, is listed as one of the most common side effects reported with lorazepam use. This is a common effect noted in official labeling.

Q: Are there common long-term effects that people experience with Lorat?

Official documents state that continuous treatment beyond approximately four months has not been systematically evaluated in clinical studies. Documented risks associated with continued use include the development of physical dependence and tolerance.

Q: Can Lorat be used for managing occasional sleep problems?

Yes, official indications include use for insomnia when it is caused by anxiety or transient situational stress. This use is generally noted in regulatory documents.

Q: What is the difference between Lorat and Valium (Diazepam)?

Regulatory classification indicates that lorazepam (Lorat) and diazepam (Valium) are both benzodiazepines. Both medications are designated as Schedule IV controlled substances in the United States.

Q: Is it common to feel 'foggy' or have trouble concentrating on Lorat?

Official labeling lists possible side effects that include decreased alertness, dizziness, and feeling lightheaded. These effects are noted in the official labeling.

Q: Is Lorat ever used before medical procedures to help with nervousness?

Yes, the injectable form of lorazepam is officially indicated for use as preanesthetic medication. Its purpose in this context is to produce sedation, relieve anxiety, and help diminish the recollection of events related to the procedure.

Q: Does using Lorat affect driving or operating machinery?

Official warnings state that because lorazepam can impair alertness, coordination, and thinking skills, patients should avoid operating dangerous machinery or motor vehicles.

Q: Is it possible to become dependent on Lorat?

Official information states that the use of lorazepam exposes users to the risks of developing physical dependence and addiction. These risks are documented to be present even when the medication is taken as prescribed.

Q: Are there any warnings for people with liver or kidney issues when using Lorat?

Regulatory documents advise caution for patients with severe hepatic insufficiency (severe liver problems) and/or hepatic encephalopathy. Official documents note that use may potentially worsen hepatic encephalopathy in this population.

Q: Can Lorat be prescribed for children or teenagers?

According to official labeling notes that the safety and effectiveness of the oral tablets and concentrate have not been established in pediatric patients under 12 years of age.

Q: What does official research say about the effectiveness of Lorat?

Lorazepam is officially indicated for the management of anxiety disorders or for the short-term relief of anxiety symptoms. This indication is based on the results of clinical experience.

Q: Is Lorat commonly used for non-anxiety related conditions?

The official indications for lorazepam include uses beyond general anxiety management. These indications include preanesthetic sedation before a procedure and, in its injectable form, the treatment of status epilepticus (a type of seizure emergency).

Q: Why is Lorat sometimes called a 'benzodiazepine'?

Lorazepam is officially described as belonging to the benzodiazepine class of drugs. This class of medications acts on the central nervous system to reduce nerve activity.

Q: Is it normal to feel a bit dizzy when first starting Lorat?

Dizziness is listed in the official adverse reactions section as one of the most common side effects reported with lorazepam use.

Q: Does Lorat interact with herbal supplements like St. John's Wort?

Regulatory guidance notes that combinations with herbal remedies intended for anxiety or insomnia, such as valerian or passionflower, should be avoided. This is because these combinations may increase the sedative effects of lorazepam.

Q: Do studies suggest any potential for memory problems with Lorat use?

Yes, official product labeling lists trouble remembering, learning, or concentrating among the possible side effects of the medication.

Q: What should a person do if they suspect a serious side effect from Lorat?

The FDA provides a system for patients and healthcare providers in the United States to report any suspected negative side effects directly to the agency. This helps monitor the safety of medications.

Q: Are there any risks associated with taking Lorat while pregnant or breastfeeding?

Official labeling warns that using lorazepam late in pregnancy can potentially result in sedation or withdrawal symptoms in the newborn. The drug is found in breast milk, and caution is noted regarding its use while nursing.

Q: Do people typically build up a tolerance to Lorat over time?

Yes, official documents note that tolerance to the effects of lorazepam is a documented risk associated with continued use of the drug.

Q: What are the most common reported side effects for Lorat?

According to official labeling, the most common reported side effects include sedation, dizziness, weakness, and feeling unsteady or uncoordinated.

Q: Is Lorat used in emergency situations?

Yes, the injectable form of lorazepam is officially indicated for use in the treatment of status epilepticus, which is a medical emergency characterized by prolonged seizures.

Q: Can I take Lorat if I have a history of glaucoma?

Lorazepam is officially contraindicated, meaning it should not be used, in patients who have acute narrow-angle glaucoma.

Q: Are mood changes a known side effect of Lorat?

Official labeling warns that pre-existing depression may emerge or worsen during treatment with lorazepam. Patients are recommended to be monitored for new or increased feelings of anxiety or depression.

Q: Does Lorat affect blood pressure?

Hypotension (low blood pressure) is noted in regulatory documents as a possible adverse effect. This risk is particularly noted when the medication is administered intravenously or co-administered with certain other drugs.

Q: Can Lorat be used by people with a history of substance abuse?

Official information notes that the use of lorazepam in patients with a history of substance abuse requires caution. This is due to the risks of abuse, misuse, and addiction, and monitoring for signs of abuse or misuse is noted as important.

Q: What is the typical time frame for re-evaluating the need for Lorat?

Official documents state that effectiveness for long-term use (more than four months) has not been assessed. Therefore, the prescribing physician should periodically reassess the continued usefulness of the medication for the individual patient.

How should Lorat (Lorazepam) be stored and disposed of?

Storage Requirements

Storage conditions for Lorazepam are highly specific to the formulation. Tablets must be stored at controlled room temperature (20 C to 25 C), in a tight, light-resistant container with a child-resistant closure. In contrast, the oral concentrate requires refrigerated storage (2 C to 8 C). The oral solution and sublingual tablets must also be protected from light. All forms must be kept out of the sight and reach of children and stored safely as a controlled substance to prevent misuse.

Stability and Disposal

The oral concentrate must be discarded after 90 days from the date of first opening, and similar post-opening limits apply to the oral solution. Disposal of any unused or expired product must be carried out in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lorat (Lorazepam) found in:

A-Z Index: